Page 450 - Williams Hematology ( PDFDrive )

424 Part V: Therapeutic Principles Chapter 27: Vaccine Therapy 425

18. Wierda WG, Cantwell MJ, Woods SJ: CD40-ligand (CD154) gene therapy for chronic 32. Pardoll DM: Spinning molecular immunology into successful immunotherapy. Nat Rev
lymphocytic leukemia. Blood 96:2917, 2000. Immunol 2:227, 2002.
19. Neelapu SS, Gause BL, Harvey L, et al. A novel proteoliposomal vaccine induces antitu- 33. Surh CD, Sprent J: Regulation of mature T cell homeostasis. Semin Immunol 17:183,
mor immunity against follicular lymphoma. Blood 109:5160, 2007. 2005.
20. Liu YJ: Dendritic cell subsets and lineages, and their functions in innate and adaptive 34. Simon RM, Steinberg SM, Hamilton M, et al: Clinical trial designs for the early clinical
immunity. Cell 106:259, 2001. development of therapeutic cancer vaccines. J Clin Oncol 19:1848, 2001.
21. Cerundolo V, Hermans IF, Salio M: Dendritic cells: A journey from laboratory to clinic. 35. Lyerly HK: Quantitating cellular immune responses to cancer vaccines. Semin Oncol
Nat Immunol 5:7, 2004. 30(3 Suppl 8):9, 2003.
22. Biragyn A, Kwak LW: Designer cancer vaccines are still in fashion. Nat Med 6:966, 2000. 36. Lee PP, Yee C, Savage PA, et al: Characterization of circulating T cells specific for
23. Tartour E, Benchetrit F, Haicheur N, et al: Synthetic and natural non-live vectors: tumor-associated antigens in melanoma patients. Nat Med 5:677, 1999.
Rationale for their clinical development in cancer vaccine protocols. Vaccine 20 37. Lynch RG, Graff RJ, Sirisinha S, et al: Myeloma proteins as tumor-specific transplanta-
(Suppl 4):A32, 2002. tion antigens. Proc Natl Acad Sci U S A 69:1540, 1972.
24. Zhang L, Tang Y, Akbulut H, et al: An adenoviral vector cancer vaccine that delivers a 38. Stevenson GT, Elliott EV, Stevenson FK: Idiotypic determinants on the surface of
tumor-associated antigen/CD40-ligand fusion protein to dendritic cells. Proc Natl Acad immunoglobulin of neoplastic lymphocytes: A therapeutic target. Fed Proc 36:2268,
Sci U S A 100:15101, 2003. 1977.
25. Kreig AM: CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 39. Kwak LW, Campbell MJ, Czerwinski DK, et al: Induction of immune responses in
20:709, 2002. patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed
26. Waldmann TA, Dubois S, Tagaya Y: Contrasting roles of IL-2 and IL-15 in the life and by their tumors. N Engl J Med 327:1209, 1992.
death of lymphocytes: Implications for immunotherapy. Immunity 14:105, 2001. 40. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev
27. Qazilbash MH, Wieder ED, Thall PF, et al: PR1 peptide vaccine-induced immune Cancer 12:252, 2012.
response is associated with better event-free survival in patients with myeloid leukemia. 41. Hsu FJ, Caspar CB, Czerwinski D, et al: Tumor-specific idiotype vaccines in the treat-
Blood 110:Abstract 283, 2007. ment of patients with B-cell lymphoma—Long-term results of a clinical trial. Blood
28. Rezvani K, Yong AS, Tawab A, et al: Ex vivo characterization of polyclonal memory 89:3129, 1997.
CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblas- 42. Dranoff G, Jaffee E, Lazenby A, et al: Vaccination with irradiated tumor cells engi-
tic leukemia and acute and chronic myeloid leukemia. Blood 113:2245, 2009. neered to secrete murine granulocyte-macrophage colony-stimulating factor stimu-
29. Oka Y, Tsuboi A, Taguchi T, et al: Induction of WT1 (Wilms’ tumor gene)-specific cyto- lates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A
toxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc 90:3539, 1993.
Natl Acad Sci U S A 101:13885, 2004. 43. Kwak LW, Young HA, Pennington RW, et al: Vaccination with syngeneic lymphoma-
30. Brentjens RJ, Rivière I, Park JH, et al: Safety and persistence of adoptively transferred derive immunoglobulin idiotype combined with granulocyte/macrophage colony-
autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci U
B-cell leukemias. Blood 118:4817, 2011. S A 93:10972, 1996.
31. Bocchia M, Gentili S, Abruzzese E, et al: Effect of a p210 multipeptide vaccine associ-
ated with imatinib or interferon in patients with chronic myeloid leukaemia and persis-
tent residual disease: A multicentre observational trial. Lancet 365:657, 2005.

Kaushansky_chapter 27_p0421-0426.indd 425 9/17/15 6:02 PM